U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07088757) titled 'Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis' on July 19.
Brief Summary: Endoscopic Retrograde Cholangiopancreatography (ERCP) is a widely used procedure for diagnosing and treating pancreatic and biliary diseases. Despite its benefits, ERCP carries a risk of post-procedure pancreatitis (PEP), which occurs in approximately 12.2% of cases and can significantly increase healthcare costs and patient morbidity. Preventing PEP is crucial for improving patient outcomes and reducing the economic burden of ERCP.
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, have been shown to be effect...